Does the LKB1–AMPK (AMP-activated protein kinase) pathway act to suppress tumorigenesis or to rescue cancer cells from metabolic collapse? New work from the Alessi laboratory in this issue of the Biochemical Journal shows conclusively that AMPK activators delay the growth of tumours that occur spontaneously in PTEN (phosphatase and tensin homologue deleted on chromosome 10) heterozygous mice.
Commentary| May 14 2008
Cancer therapy: staying current with AMPK
David A. Fruman;
David A. Fruman 1
*Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA 92697, U.S.A.
†Center for Immunology, University of California Irvine, Irvine, CA 92697, U.S.A.
1To whom correspondence should be addressed (email email@example.com).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
David A. Fruman, Aimee L. Edinger; Cancer therapy: staying current with AMPK. Biochem J 1 June 2008; 412 (2): e3–e5. doi: https://doi.org/10.1042/BJ20080823
Download citation file: